Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Alpha-Lipoic Acid as Add-on Therapy to Dapagliflozin on Insulin Resistance and Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

NCT07934225 is registered in ClinicalTrials.gov with Fayoum University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07934225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Alpha-Lipoic Acid as Add-on Therapy to Dapagliflozin on Insulin Resistance and Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Lead sponsor
Fayoum University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
September 1, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, insulin resistance syndrome

Arms

As registered; 2 arms.

  • ALA + Metformin/Dapagliflozin Active comparatorAlpha-Lipoic Acid (ALA)

    Alpha-lipoic acid 600 mg capsule taken orally once daily for 12 weeks, in addition to the participant's usual metformin and dapagliflozin 10 mg daily, which continue unchanged.

  • Placebo + Metformin/Dapagliflozin Placebo comparatorPlacebo

    Matching placebo capsule taken orally once daily for 12 weeks, in addition to the participant's usual metformin and dapagliflozin 10 mg daily, which continue unchanged.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Baseline to Week 12

    HOMA-IR = fasting insulin (microunits/mL) x fasting glucose (mg/dL) / 405, calculated from fasting blood samples. Change = Week 12 value minus baseline value.

Lead sponsor's other trials

Fayoum University, most recent start first.

Similar trials

Same condition (Metabolic Syndrome) and phase, most recent start first.